[Buserelin--a GnRh analog for the treatment of endometriosis].

article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-11

This study evaluated Buserelin's effectiveness in treating endometriosis, finding it reduced disease while endometriomas showed minimal response, and was well-tolerated with few side effects and increased pregnancy rates.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Within the scope of an open study, the results after treatment with Buserelin for patients with endometriosis is appraised. The patients are studied by laparoscopy or laparotomy before and after a six-month-long treatment. A clear decline of the endometriosis can be seen; however, endometriomas showed little or no reaction. The Buserelin therapy is shown to be well tolerated. It increases the rate of pregnancies, gives few biochemical complications and is an entirely acceptable therapy with few side effects. Buserelin offers a real alternative for the pharmacotherapy of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Administration, Intranasal Adult Buserelin Buserelin Drug Evaluation Endometriosis Female Humans Laparoscopy Laparotomy

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-04T06:17:57.233406+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0 · commercial use OK